A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)

An open-label, multicenter, phase IIIb, single-arm study to evaluate the safety and efficacy of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a wide patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, II (subset) or I (high-risk subset as exploratory cohort) early Breast Cancer (EBC)

开始日期2025-04-30

申办/合作机构

Novartis Pharmaceuticals Corp.

NCT06726148 / Not yet recruiting临床1/2期

An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors

Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies.
Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

开始日期2025-03-26

申办/合作机构

Novartis Pharmaceuticals Corp.

NCT06377852 / Recruiting临床3期IIT

Comparing Oral Drug Dosing Strategies in Older Patients With Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs.
The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally daily on days 1-21 of 28-day cycle) vs. TTD using titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) or ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice endocrine therapy (aromatase inhibitor (AI) or fulvestrant) in patients age 65 or older with HR+/HER2- MBC. The secondary and exploratory objectives will generate evidence needed to personalize treatment decisions by comparing patient-centric secondary outcomes and evaluating baseline factors.
Together with their treating physician, participants will choose the CDK4/6 inhibitor (palbociclib or ribociclib) and which endocrine therapy (aromatase inhibitor or fulvestrant) of their choice but will be randomized to either Arm 1 (indicated dosing) or Arm 2 (titrated dosing).

开始日期2024-10-29

申办/合作机构

American Society of Clinical Oncology, Inc.

[+1]

100 项与琥珀酸瑞波西利相关的临床结果

登录后查看更多信息

100 项与琥珀酸瑞波西利相关的转化医学

登录后查看更多信息

100 项与琥珀酸瑞波西利相关的专利（医药）

登录后查看更多信息

810

项与琥珀酸瑞波西利相关的文献（医药）

2025-03-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Three sample preparation methods for clinical determination of CDK4/6 inhibitors with endocrine therapy in breast cancer patient plasma using LC-MS: Cross-validation (red), ecological (green) and economical (blue) assessment

Article

作者: Mlinarić, Zvonimir ; Turković, Lu ; Sertić, Miranda ; Lovrić, Mila ; Silovski, Tajana ; Nigović, Biljana

Cyclin D-dependent kinase 4/6 inhibitors palbociclib, ribociclib and abemaciclib, in combination with aromatase inhibitors anastrozole and letrozole or oestrogen receptor degrader fulvestrant, are being assessed as candidates for therapeutic drug monitoring. An ideal bioanalytical method for their determination in patient plasma samples is therefore of high interest, as there is no routine reference method yet available in the clinical practice. In this work, three sample preparation approaches - dispersive liquid-liquid microextraction (DLLME), solid-phase extraction (SPE), and newly developed phospholipid removal (PLR) for LC-MS determination of these six drugs are comprehensively assessed. The methods are validated in the clinically relevant linear ranges with remarkable precision (RSD ≤6.9 %) and accuracy (bias -13.6 - 11.8 %). To compare the procedures in a real-world setting, they are applied on 38 samples from breast cancer patients. The differences between paired results are below 20 % for more than 92 % of the repeats and the RSD is ≤13.1 % between the corresponding results. Statistical comparison of the results reveals excellent overall agreement between the methods (Lin's concordance correlation coefficient ≥0.9969, maximal Bland-Altman bias 6.3 %). DLLME proved to be the most ecologically acceptable method due to the high degree of miniaturisation (AGREEprep score 0.44), PLR enabled very high sample throughput and cost-effectiveness (BAGI 72.5), while SPE showed the best analytical performance (redness score 100). All three methods are suitable for their designated purpose, and the choice of the ideal method can be made based on the scope of application, available funds and equipment and desired ecological footprint.

2025-02-01·BREAST

Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis

Review

作者: De Santis, Pierluigi ; Pagliuca, Martina ; Arpino, Grazia ; De Laurentiis, Michelino ; Giuliano, Mario ; De Angelis, Carmine ; Pavone, Giuliana ; Longobardi, Alessandra ; Caputo, Roberta ; Caltavituro, Aldo ; Puglisi, Fabio ; Del Mastro, Lucia ; Tafuro, Margherita ; Buonaiuto, Roberto

BACKGROUND:

The combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard of care for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (aBC). While the efficacy and safety profiles of CDK4/6i and ET have been extensively evaluated in phase II and III trials worldwide, it remains unclear whether the response to CDK4/6i and toxicity profile vary among Asian and non-Asian patients. Therefore, we aimed to assess the treatment efficacy of ET with and without CDK4/6i by comparing outcomes in Asian and non-Asian subgroups included in these clinical trials. In addition, we evaluated the toxicity profiles of the treatments by estimating the risk of treatment-related adverse events (AEs).

METHODS:

We conducted a meta-analysis including the most recent randomized trial data systematically searched from PubMed, Embase, Web of Science, Cochrane CENTRAL (from inception to May 31st, 2024) or presented in abstracts or oral presentations at the ESMO, ASCO, and SABCS international congresses. We included studies comparing CDK4/6i (palbociclib, ribociclib, abemaciclib, dalpiciclib) + ET versus placebo + ET. Progression-free survival (PFS) and overall survival (OS), hazard ratios (HR), and 95 % confidence intervals (CI) were extracted for the two subgroups of interest. To evaluate the treatment-related toxicity profiles, we extracted the number of side effects to estimate the risk of treatment-emergent AEs.

RESULTS:

Eleven studies (n = 5129) were included in this meta-analysis. The addition of CDK4/6i to ET consistently improved PFS in both Asian (HR = 0.52, 95 % CI 0.47-0.60; p < 0.001) and non-Asian (HR = 0.58, 95 % CI 0.52-0.64; p < 0.001) groups. Similarly, the combination of CDK4/6i + ET led to an OS improvement in both Asian (HR = 0.75, 95 % CI 0.62-0.91; p = 0.003) and non-Asian (HR = 0.81, 95 % CI 0.73-0.89; p < 0.001) patients. The risk of treatment related toxicity was higher in the CDK4/6i + ET arm in both Asian and non-Asian groups. Interestingly, a numerically higher rate of treatment-related hematological toxicity was observed in Asian patients, although no significant interethnic difference was found in the relative risk of these events.

CONCLUSIONS:

The combination of CDK4/6i and ET significantly improves PFS and OS compared to ET alone in both Asian and non-Asian patients with HR+/HER2-aBC. Although the magnitude of benefit appears to be independent of ethnicity, future clinical trials should devise a standardized method for stratifying patients by ethnicity to more effectively assess potential differences in treatment benefits.

SYSTEMATIC REVIEW REGISTRATION:

PROSPERO registration number: CRD42024543217.

2024-12-31·Future Science OA

Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review

Review

作者: Kümler, Iben ; Christiansen, Emilie Adrian

Approximately 70% of newly diagnosed breast cancers are of the HR+/HER2- subtype. For the treatment of patients with HR+/HER2- metastatic breast cancer, current guidelines recommend the use of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in combination with endocrine therapy. In this review we assess existing literature concerning real-world effectiveness of palbociclib. Survival outcomes in terms of progression-free survival and overall survival are discussed and compared among the included real-world studies and in relation to the phase III PALOMA trials.

611

项与琥珀酸瑞波西利相关的新闻（医药）

2024-12-24

·复宏汉霖

产品速递 | HLX78治疗ESR1突变ER+/HER2-乳腺癌的国际多中心III期临床研究完成中国首例患者给药

2024年12月24日，复宏汉霖（2696.HK）宣布，HLX78（lasofoxifene，拉索昔芬片）联合阿贝西利（CDK4/6 抑制剂）用于治疗既往接受过芳香化酶抑制剂（AI）治疗、雌激素受体α基因（ESR1）突变的雌激素受体阳性（ER+）、人表皮生长因子受体2阴性（HER2-）局部晚期或转移性乳腺癌患者的国际多中心III期临床研究（ELAINE-3研究，NCT05696626）完成中国首例患者给药。目前，该研究正同步于美国、加拿大、欧盟等国家和地区招募受试者。乳腺癌是全球发病率第二高的癌症，据GLOBOCAN数据显示，2022年全球乳腺癌新发病例约230万，中国乳腺癌新发病例逾35.7万[1]。雌激素受体（Estrogen receptor，ER）阳性乳腺癌占乳腺癌总数的60%-70%[2]。内分泌治疗是ER+乳腺癌的主要治疗手段，其中最常使用的芳香化酶抑制剂（aromatase inhibitor，AI）已被美国国立综合癌症网络（NCCN）和中国临床肿瘤学会（CSCO）等指南推荐成为ER+/HER2-乳腺癌患者的辅助及一线标准治疗方法[3,4]，然而几乎所有经AI治疗的患者会产生原发性或获得性耐药[5]，其中ESR1获得性突变最为常见，高达40%，被认为是内分泌治疗重要耐药机制[6]，目前针对ESR1突变的ER+/HER2-乳腺癌治疗方案有限，存在较大治疗需求。 HLX78是公司自Sermonix Pharmaceuticals, Inc. 许可引进的一款临床在研口服选择性雌激素受体调节剂 (selective estrogen receptor modulator，SERM) ，在ESR1突变的ER+/HER2-转移性乳腺癌的治疗中具有强大的靶向治疗作用。在已完成的两项II期临床研究（ELAINE-1和ELAINE-2研究）中，针对ESR1突变肿瘤，lasofoxifene作为单药或联合CDK4/6抑制剂使用均展现出抗肿瘤活性[7-8]。从lasofoxifene对雌激素受体突变的生物利用度和药物活性来看，该候选药物有望为内分泌治疗后产生获得性耐药ESR1突变的患者群体带来希望，并有望在晚期ER+乳腺癌的精准医学治疗中发挥关键作用。未来，公司也将继续以患者为中心，聚焦未满足的临床需求，垂直深耕乳腺癌领域领域，加快推进该项国际多中心临床试验进展，并以不断的创新与突破为更多病患带来更多质高价优的治疗方案。【参考文献】 [1] Bray F, Laversanne M, Sung H, et al. CA Cancer J Clin. 2024: 1-35. [2] Ignatiadis M, Sotiriou C. Luminal breast cancer: from biology to treatment[J]. Nat Rev Clin Oncol, 2013, 10(9): 494-506. doi: 10.1038/nrclinonc.2013.124. [3] Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2023. [4] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.5.2023 [5] Rozeboom B, Dey N, De P. ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future. Am J Cancer Res. 2019;9(12):2821-2831. Published 2019 Dec 1. [6] Spoerke JM, Gendreau S, Walter K, et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun. 2016;7:11579. Published 2016 May 13. doi:10.1038/ncomms11579 [7] Goetz MP, Bagegni NA, Batist G, et al. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol. 2023;34(12):1141-1151. doi:10.1016/j.annonc.2023.09.3104 [8] S. Damodaran, C.C. O’Sullivan, A. Elkhanany, I.C. Anderson, M. Barve, S. Blau, M.A. Cherian, J.A. Peguero, M.P. Goetz, P.V. Plourde, D.J. Portman, H.C.F. Moore, Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol. 2023;34(12):1131-1140. doi:10.1016/j.annonc.2023.09.3103. 关于ELAINE-3研究本研究是一项开放标签、随机、对照、多中心的III期研究，旨在比较HLX78联合阿贝西利和氟维司群联合阿贝西利治疗ER+/HER2–的局部晚期或转移性乳腺癌的男性和绝经前/后女性患者的有效性、安全性和耐受性，患者在接受芳香化酶抑制剂联合哌柏西利或瑞波西利作为一线内分泌治疗转移性疾病后出现疾病进展且携带ESR1基因突变。符合条件的受试者将以1:1的比例随机分配，接受HLX78（每日5毫克，口服）联合阿贝西利或氟维司群联合阿贝西利。本研究的主要目标是评估各治疗组的无进展生存期（PFS），评估采用盲态独立中心评估（BICR）基于实体瘤评价标准（RECIST）1.1进行。次要目标为评估其他终点，包括客观缓解率、总生存期、临床获益率、缓解持续时间、至缓解时间、至细胞毒性化疗时间、生活质量和安全性。关于复宏汉霖复宏汉霖（2696.HK）是一家国际化的创新生物制药公司，致力于为全球患者提供可负担的高品质生物药，产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域，已有6款产品在中国获批上市，3款产品在国际获批上市，25项适应症获批，4个上市申请分别获中国药监局、美国FDA和欧盟EMA受理。自2010年成立以来，复宏汉霖已建成一体化生物制药平台，高效及创新的自主核心能力贯穿研发、生产及商业运营全产业链。公司已建立完善高效的全球创新中心，按照国际药品生产质量管理规范（GMP）标准进行生产和质量管控，不断夯实一体化综合生产平台，其中，公司商业化生产基地已相继获得中国、欧盟和美国GMP认证。复宏汉霖前瞻性布局了一个多元化、高质量的产品管线，涵盖50多个分子，并全面推进基于自有抗PD-1单抗H药汉斯状®的肿瘤免疫联合疗法。截至目前，公司已获批上市产品包括国内首个生物类似药汉利康®（利妥昔单抗）、自主研发的中美欧三地获批单抗生物类似药汉曲优®（曲妥珠单抗，美国商品名：HERCESSI™，欧洲商品名：Zercepac®）、汉达远®（阿达木单抗）、汉贝泰®（贝伐珠单抗）以及汉奈佳®（奈拉替尼），此外，创新产品汉斯状®（斯鲁利单抗）已获批用于治疗微卫星高度不稳定（MSI-H）实体瘤、鳞状非小细胞肺癌、广泛期小细胞肺癌、食管鳞状细胞癌和非鳞状非小细胞肺癌，并成为全球首个获批一线治疗小细胞肺癌的抗PD-1单抗。公司亦同步就16个产品在全球范围内开展30多项临床试验，对外授权全面覆盖欧美主流生物药市场和众多新兴市场。 First Chinese Patient Dosed for Phase 3 MRCT on ER+/HER2- Breast Cancer of HLX78 Shanghai, China, December 24, 2024 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient in China has been dosed in the international multi-centre Phase 3 clinical trial (ELAINE-3, NCT05696626) of HLX78 (oral lasofoxifene) in combination with abemaciclib (a CDK4/6 inhibitor) in patients with locally advanced or metastatic estrogen receptor-positive (ER+)/Human epidermal growth factor receptor 2-negative (HER2-) breast cancer who have disease progression on an aromatase inhibitor (AI) in combination with CDK4/6 inhibitor and have an estrogen receptor α gene (ESR1) mutation. ELAINE-3 is currently recruiting subjects in the United States, Canada, the European Union, in addition to other countries and regions. Breast cancer is the second most diagnosed cancer in the world, according to GLOBOCAN 2022. There were around 2.3 million new cases of breast cancer in 2022 globally, including more than 357,000 in China.[1] ER+ breast cancer comprises 60-70% of all breast cancers.[2] Endocrine therapy remains the mainstay treatment for ER+ breast cancer and the most widely used class of aromatase inhibitor (AI) has been recommended by the National Comprehensive Cancer Network (NCCN) and Chinese Society of Clinical Oncology (CSCO) guidelines to be the adjuvant and first-line standard of care for patients with ER+/HER2- breast cancer.[3,4] However, almost all patients treated with AIs in the advanced setting develop resistance[5], with ESR1 mutations being one of the most prevalent alterations, present in up to 40% of patients and a significant mechanism of resistance to endocrine therapy[6]. Currently, there are limited treatment options for ER+/HER2- breast cancer with ESR1 mutations, and thus a large clinical need exists. HLX78 (lasofoxifene) is an oral selective estrogen receptor modulator (SERM) licensed by Henlius for Asia from Sermonix Pharmaceuticals, Inc. It has demonstrated robust target engagement in ER+/HER2- metastatic breast cancer, particularly in the presence of ESR1 mutations. In two completed Phase 2 clinal studies (ELAINE-1 and ELAINE-2), lasofoxifene has demonstrated anti-tumour activity against tumours with ESR1 mutations as monotherapy and in combination with a CDK4/6 inhibitor.[7,8] Lasofoxifene’s bioavailability and activity in mutations of the estrogen receptor could potentially hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, and, if approved, play a critical role in the precision medicine treatment of advanced ER+ breast cancer. In the future, Henlius will continue to adopt a patient-centric approach, focusing on unmet clinical needs. The company will delve deeply into the breast cancer field and expedite the development of the international multi-center clinical trial ELAINE-3, aiming to bring more high-quality, affordable, and innovative treatments to patients worldwide. About ELAINE-3 This is a phase 3, open label, controlled, randomized, multicenter study comparing the efficacy, safety, and tolerability of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib for the treatment of men and pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer who have disease progression on an aromatase inhibitor in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation. Eligible participants will be randomized at 1:1 to receive lasofoxifene (5 mg/day, oral administration) combined with abemaciclib or fulvestrant combined with abemaciclib. The primary objective of this study is to evaluate the progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 as determined by blinded independent central review of each treatment arm. The secondary objectives are to evaluate other endpoints, including objective response rate, overall survival, clinical benefit rate, duration of response, time to response, time to cytotoxic chemotherapy, quality of life, and safety. About Henlius Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 3 have been approved for marketing in overseas markets, 25 indications are approved worldwide, and 4 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP. Henlius has pro-actively built a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), the innovative product HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumors, squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC) and non-small cell lung cancer (nsNSCLC), making it the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. What’s more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets. 联系方式媒体：PR@Henlius.com 投资者：IR@Henlius.com 喜欢本文内容点击下方按钮·分享 ·收藏 ·点赞 ·在看

CSCO会议临床3期临床1期临床2期

2024-12-23

·GlobeNewswire-Health Care

Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis

In the largest study to date of bone and soft tissue tumors, OGM detected 100% of the variants found by multiple standard techniques, including karyotyping, fluorescent in-situ hybridization (FISH) & gene fusion assaysOGM was also more sensitive, including detection of diagnostic or pathogenic variants missed by karyotype in 74% (14/19) of cases that failed or were negative by karyotypingWhen OGM results and next-generation sequencing (NGS) results were combined, diagnostic and pathogenic structural variants (SVs), copy number variants (CNVs), and/or single nucleotide variants (SNVs) were found in ~98% of cases, a substantially greater rate than when karyotyping, FISH and NGS are used SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Modern Pathology by a group of researchers at the Johns Hopkins University School of Medicine, showing that optical genome mapping (OGM) can outperform traditional techniques in analysis of bone and soft tissue tumors. Several prior publications have shown the utility of OGM compared to traditional cytogenetics in studies of hematologic malignancies, however, data on the application of OGM in solid tumors has been relatively sparse. This study provides compelling support for extending the utility of OGM in cancer beyond hematologic malignancies to solid tumors. Key findings: OGM detected all variants revealed by conventional cytogenetics: OGM showed 100% concordance, identifying all pathogenic variants detected by standard of care cytogenetic methods. The specificity of OGM was assessed to be 100%, i.e. OGM correctly identified the same pathogenic SVs and CNVs detected by standard of care/routine cytogenetics (karyotyping and FISH).OGM detected pathogenic variants missed by karyotyping: In 74% of cases with normal or failed karyotype, OGM detected diagnostic or pathogenic SVs that were missed by karyotyping. Further, in 6 cases that failed to yield any karyotyping results due to culture failure, OGM detected pathogenic SVs in all of them. Variants found by OGM but missed by standard of care included the EWSR1::ETV1 fusion, which is a key molecular hallmark of clear cell sarcoma and helps to differentiate it from other soft tissue sarcomas and melanomas.OGM resolved complex cancer genomes: Study authors found that OGM data could re-characterized and better defined complex structural rearrangements including chromoanagenesis in 27% of cases and complex 3-6-way translocations in 15% of cases when compared to traditional cytogenetic methods.OGM combined with NGS found pathogenic variants in 98% of cases, a substantially greater rate than when karyotyping, FISH and NGS are used: The integrated approach of the combination of OGM and NGS resulted in the detection of pathogenic SVs and sequence variants in ~98% of cases. OGM was 100% concordant with NGS for aneuploidy detection.OGM findings have the potential to qualify subjects for targeted therapies that otherwise would not have been possible: The authors state that several of the OGM findings could result in the potential for these cases to qualify for either targeted treatments or clinical trials. For example, cases with potential to be treated by CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), TRK inhibitors (larotrectinib, entrectinib), pan-FGFR inhibitors (erdafitinib or futibatinib) were highlighted. Erik Holmlin, president and chief executive officer of Bionano commented, “Approximately 50% of bone and soft tissue tumor samples fail to reveal actionable information for proper classification of disease, prognosis and therapeutic management because they either fail to culture or because traditional techniques in cytogenetics lack adequate sensitivity and specificity to reliably detect relevant variants. We have seen increasing evidence for OGM as a valuable alternative to cytogenetic methods in blood cancers, and we are thrilled to see researchers at Johns Hopkins publishing this compelling case for extending OGM’s utility to bone and soft tissue tumors.” The full research publication is available at: https://doi.org/10.1016/j.modpat.2024.100684 About Bionano Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For more information, visit www.bionano.com or www.bionanolaboratories.com. Bionano’s products are for research use only and not for use in diagnostic procedures. Forward-Looking Statements of Bionano Genomics This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “can,” “could,” “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, OGM’s utility for applications in bone and soft tissue cancers; OGM’s ability to detect SVs and CNVs concordant with traditional cytogenetic methods, including karyotyping and FISH; OGM’s ability to detect SVs and CNVs not detected with transitional cytogenetic methods; the utility and ability of OGM to detect diagnostically relevant or pathogenic SVs and CNVs; the ability of OGM and NGS in combination to detect more SVs than when combining karyotyping, FISH and NGS; the potential for OGM to be useful in qualifying subjects for targeted therapies or clinical trials; the utility of OGM for uses described in the publication referenced in this press release; the ability of OGM to re-characterized and better defined complex structural rearrangements when compared to traditional cytogenetic methods; OGM’s ability and utility for adoption across a wider spectrum of cancers including blood, bone and soft tissue cancers and the increase in adoption and utilization as an alternative to traditional cytogenetic methods; the utility of OGM for applications in areas reported in this press release; and other statements that are not historical facts. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as recent and potential bank failures, supply chain disruptions, global pandemics, inflation, and the ongoing conflicts between Ukraine and Russian and Israel and Hamas, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; the failure of OGM to prove useful for applications in bone and soft tissue cancers; the failure of OGM to detect SVs concordant with traditional cytogenetic methods, including karyotyping and FISH; the failure of OGM to detect SVs and CNVs not detected with transitional cytogenetic methods; the failure of OGM to detect diagnostically relevant or pathogenic SVs and CNVs; the failure of OGM to prove useful for applications described in the publication referenced in this press release; the failure of OGM to be more widely adopted across a wider spectrum of cancers including blood, bone and soft tissue cancers and the increase in adoption and utilization as an alternative to traditional cytogenetic methods; the failure of OGM and NGS in combination to detect more SVs than when combining karyotyping, FISH and NGS; the failure of OGM to be useful in qualifying subjects for targeted therapies or clinical trials; the failure of OGM to prove useful for applications in areas reported in this press release; the failure of OGM to re-characterized and better defined complex structural rearrangements when compared to traditional cytogenetic methods future publications that contradict the findings of the publication referenced in this press release; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; our ability to effectively manage our uses of cash, and our ability to continue as a “going concern”; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com Investor Relations:David HolmesGilmartin Group+1 (858) 888-7625IR@bionano.com

寡核苷酸

2024-12-22

·药渡

全球畅销肿瘤药图鉴

作者：布布随着对癌症医治的需求不断上升，促进了高效医治方法的进展，尤其是精确医疗和免疫疗法的提升。这些革新带来了庞大的经济收益，2024年抗癌药品市场实现了关键进展，销售业绩突出。 Keytruda (pembrolizumab) · 首次获批时间：2014年9月14日 · 开发商：默沙东 · 模态：单抗 · 作用机制：PD-1抑制剂（免疫检查点抑制剂） · 获批适应症：黑色素瘤、转移性非小细胞肺癌、头颈癌、霍奇金淋巴瘤、尿路上皮癌、胃癌、宫颈癌、肝细胞癌、默克尔细胞癌、肾细胞癌、食道癌、子宫内膜癌、鳞状细胞癌、肝细胞癌、乳腺癌、胆道肿瘤、恶性胸膜间皮瘤 · 2024年Q3销售额：74.29亿美元 · 2024年Q3销售额同比变化：17% · 销售额变化动力：Keytruda销售额增长的推动因素包括全球对早期适应症的接受度增加，包括三阴性乳腺癌 (TNBC)、肾细胞癌 (RCC) 和非小细胞肺癌 (NSCLC)，以及全球对转移性适应症的持续强劲需求。 · 关键专利到期：2028年 · 预计峰值销售额：312.8亿美元（2027年） Darzalex (daratumumab) · 首次获批时间：2015年11月16日 · 开发商：强生/Genmab · 模态：单抗 · 作用机制：抗 CD38 单体 · 获批适应症：多发性骨髓瘤 · 2024年Q3销售额（净销售额）：30.16亿美元 · 2024年Q3（净）销售额同比变化：21% · 销售额变化动力：Darzalex Q3销售额增长的主要动力来源于其在治疗多发性骨髓瘤中的持续成功和广泛应用。尤其是在全球市场的扩展和联合治疗中的应用增长显著，例如在澳大利亚，其销售额在补贴政策下同比大幅增长。 · 关键专利到期：2032年 · 预计峰值销售额：168.7亿美元（2028年） Opdivo (nivolumab) · 首次获批时间：2014年12月22日 · 开发商：百时美施贵宝 · 模态：单抗 · 作用机制：PD-1抑制剂（免疫检查点抑制剂） · 获批适应症：黑色素瘤、转移性非小细胞肺癌、肾细胞癌、霍奇金淋巴瘤、头颈癌、尿路上皮癌、结直肠癌、肝细胞癌、食道癌、恶性胸膜间皮瘤、胃癌 · 2024年Q3销售额：23.6亿美元 · 2024年Q3销售额同比变化：4% · 销售额变化动力：作为成熟的PD-1抑制剂，Opdivo的销售增长已趋于稳定，市场需求不如其推出初期那么强劲。另外，FDA正在考虑是否缩小Opdivo在PD-L1阴性胃癌和食管癌中的适应症范围，这种不确定性可能使一些医生对该药物的使用更加谨慎，从而影响其销售表现。对于一款专利即将到期的超级重磅炸弹，Opdivo销售额增长势头减缓也是必然的现象。 · 关键专利到期：2028年 · 预计峰值销售额：134.5亿美元（2027年） Tagrisso (Osimertinib) · 首次获批时间：2015年12月13日 · 开发商：阿斯利康 · 模态：小分子 · 作用机制：表皮生长因子受体 (EGFR) 酪氨酸激酶抑制剂 (TKI)，可与某些 EGFR 突变形式（T790M、L858R 和外显子 19 缺失）结合，这些突变形式在接受一线 EGFR-TKI 治疗后在非小细胞肺癌 (NSCLC) 肿瘤中占主导地位。 · 获批适应症：非小细胞肺癌 · 2024年Q3销售额：16.7亿美元 · 2024年Q3销售额同比变化：14% · 预计峰值销售额：102.7亿美元（2028年） Imbruvica（Ibrutinib） · 首次获批时间：2013年11月13日 · 开发商：强生/艾伯维 · 模态：小分子 · 作用机制：布鲁顿酪氨酸激酶（BTK）不可逆强效共价抑制剂。它与 BTK 活性位点 (Cys481) 中的半胱氨酸残基形成共价键，从而抑制 BTK。BTK 的抑制在 B 细胞受体信号传导中发挥作用，Ibrutinib的抑制作用可防止下游底物（如 PLC-γ）的磷酸化。 · 获批适应症：慢性淋巴细胞白血病、瓦尔登斯特伦巨球蛋白血症、移植物抗宿主病等 · 2024年Q3销售额：8.28亿美元（艾伯维）、7.53亿美元（强生） · 2024年Q2销售额同比变化率：-8.8%（艾伯维）、-6.8%（强生） · 销售额变化原因：Imbruvica在2024年第三季度销售额同比下降的主要原因是其面临着来自新疗法的竞争压力以及市场环境的变化，特别是针对B细胞受体通路的靶向疗法，例如acalbrutinib（Calquence）等。 · 关键专利到期：2036年 Xtandi（enzalutamide） · 首次获批时间：2012年8月31日 · 开发商：安斯泰来/辉瑞 · 模态：小分子 · 作用机制：第二代抗雄激素，可阻断前列腺癌中的雄激素和雄激素受体 (AR) 的活性。Enzalutamide可以抑制细胞生长并诱导细胞凋亡。 · 获批适应症：前列腺癌 · 2024年Q3销售额：5.61亿美元（辉瑞）；安斯泰来第三季度数据尚未公布 · 2024年Q3销售额同比变化：28%（辉瑞） · 销售额变化动力：Xtandi 的运营收入增长的主要原因是由于 2023 年第四季度获批后，非转移性去势敏感前列腺癌 (nmCSPC) 适应症的采用带来了强劲的需求。 · 关键专利到期：2027年 Revlimid（lenalidomide） · 首次获批时间：2005年12月27日 · 开发商：百时美施贵宝 · 模态：小分子 · 作用机制：Lenalidomide通过改变细胞因子产生 (抑制促炎细胞因子的产生)、调节 T 细胞共刺激和增强 NK 细胞介导的细胞毒性来发挥免疫调节作用。 · 获批适应症：骨髓增生异常综合征、多发性骨髓瘤、淋巴瘤、滤泡性淋巴瘤 · 2024年Q3销售额：14.12亿美元 · 2024年Q3销售额同比变化率：-1% · 销售额变化原因：仿制药上市 Verzenio (abemaciclib) · 首次获批时间：2017年9月28日 · 开发商：礼来 · 模态：小分子 · 作用机制：Abemaciclib 是细胞周期依赖性蛋白激酶 4 (CDK4) 和 6 (CDK6) 的双重抑制剂，它们参与细胞周期并在活动失调时促进癌细胞生长。 · 适应症：乳腺癌 · 2024年Q3销售额：13.7亿美元 · 2024年Q3销售额同比变化：32% · 销售额变化动力：主要得益于晚期或转移性乳腺癌中的应用得到更广泛的接受。随着更多的患者和医疗提供者使用Verzenio，药物的市场需求显著上升，进一步推动了销售增长。 · 关键专利到期：2031年 Imfinzi (durvalumab) · 首次获批时间：2017年5月1日 · 开发商：阿斯利康 · 模态：单抗 · 作用机制：Durvalumab属于免疫检查点抑制剂。Durvalumab 是PD-L1的阻断抗体，可促进攻击肿瘤细胞的正常免疫反应。 · 适应症：非小细胞肺癌、小细胞肺癌、胆道肿瘤、肝细胞癌、子宫内膜癌等 · 2024年Q3销售额：12.03亿美元 · 2024年Q3销售额同比变化率：13% Ibrance (palbociclib) · 首次获批时间：2015年2月3日 · 开发商：辉瑞 · 模态：小分子 · 作用机制：细胞周期依赖性激酶 CDK4 和 CDK6 选择性抑制剂。 · 适应症：乳腺癌 · 2024年Q3销售额：12.44亿美元 · 2024年Q3销售额同比变化：-13% · 销售额变化原因：Ibrance面临来自其他CDK4/6抑制剂的强烈竞争，特别是来自诺华的Kisqali和礼来的Verzenio。这些药物在临床数据上有所突破，尤其是在延长患者总生存期方面表现得更为突出。 · 关键专利到期：2027年 Tecentriq (atezolizumab) · 首次获批时间：2016年5月18日 · 开发商：罗氏 · 模态：单抗 · 作用机制：PD-L1抑制剂 · 适应症：非小细胞肺癌、小细胞肺癌、肝细胞癌、黑色素瘤、肺泡软组织肉瘤 · 2024年Q3销售额：10.38亿美元 · 2024年Q3销售额同比变化：0% · 关键专利到期：2032年 · 预计峰值销售额：76.5亿美元（2028年） Kisqali (ribociclib) · 首次获批时间：2017年3月13日 · 开发商：诺华 · 模态：小分子 · 作用机制：细胞周期依赖性激酶 (CDK) 4 和 6 的抑制剂 · 适应症：乳腺癌 · 2024年Q3销售额：7.87亿美元 · 2024年Q3销售额同比变化：43% · 销售额变化动力：得益于在 HR+/HER2- 晚期乳腺癌中的总体生存益处得到越来越多的认可以及 1 类 NCCN 指南推荐。 · 关键专利到期：2036年 · 预计峰值销售额：69.7亿美元（2028年） Calquence (acalabrutinib) · 首次获批时间：2017年10月31日 · 开发商：阿斯利康 · 模态：小分子 · 作用机制：布鲁顿酪氨酸激酶 (BTK) 抑制剂 · 适应症：套细胞淋巴瘤；慢性淋巴细胞白血病 · 2024年Q3销售额：8.13亿美元 · 2024年Q3销售额同比变化：24% · 关键专利到期：2036年 · 预计峰值销售额：40.2亿美元（2028年） Lynparza (olaparib) · 首次获批时间：2014年12月19日 · 开发商：阿斯利康 · 模态：小分子 · 作用机制：聚 ADP 核糖聚合酶 (PARP) 抑制剂 · 适应症：卵巢癌、输卵管癌、腹膜癌、乳腺癌、胰腺癌、前列腺癌 · 2024年Q3销售额：7.78亿美元 · 2024年Q3销售额同比变化：11% · 关键专利到期：2029年 · 预计峰值销售额：39.3亿美元（2027年） Carvykti (ciltacabtagene autoleucel) · 首次获批时间：2022年2月28日 · 开发商：强生 · 模态：细胞疗法 · 作用机制：针对 BCMA 的 CAR-T · 适应症：多发性骨髓瘤 · 2024年Q3销售额：2.86亿美元 · 2024年Q3销售额同比变化：87.7% · 销售额变化动力：CARVYKTI 是第一个也是唯一一个相较于标准疗法能够显著延长多发性骨髓瘤患者二线治疗总生存期的细胞疗法。 · 预计峰值销售额：38.9亿美元（2028年） Pluvicto (lutetium lu 177 vipivotide tetraxetan) · 首次获批时间：2022年3月23日 · 开发商：诺华 · 模态：多肽药物偶联物 · 作用机制：放射性配体治疗剂 · 适应症：前列腺癌 · 2024年Q3销售额：3.86亿美元 · 2024年Q3销售额同比变化：50% · 销售额变化动力：第三季度销售额受益于欧洲一次性收入扣除调整。由于供应现在不受限制，重点是增加现有 RLT （Radioligand Therapy）站点的份额，同时开设新站点和转诊途径，并吸引新患者。 · 预计峰值销售额：38.7亿美元（2028年） Ref. Merck Announces Third-Quarter 2024 Financial Results. Merck & Co. Press Release. 31. 10. 2024. Manalac, T. J&J Gets Q3 Beat, Raises Full-Year Guidance on Strong Darzalex Sales. Biospace. 15. 10. 2024. Bristol Myers Squibb Reports Third Quarter Financial Results for 2024. BMS Press Release. 31. 10. 2024. Johnson & Johnson Reports Q3 2024 Results. J&J Press Release. 15. 10. 2024. AbbVie Reports Third-Quarter 2024 Financial Results. AbbVie Press Release. 30. 10. 2024. 药渡媒体商务合作媒体公关 | 新闻&会议发稿张经理：18600036371（微信同号）点击下方“药渡“，关注更多精彩内容免责声明 “药渡”公众号所转载该篇文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请及时告知，我们会在24小时内删除相关信息。微信公众号的推送规则又双叒叕改啦，如果您不点个“在看”或者没设为"星标"，我们可能就消散在茫茫文海之中~点这里，千万不要错过药渡的最新消息哦！👇👇👇

专利到期免疫疗法上市批准

100 项与琥珀酸瑞波西利相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	琥珀酸瑞波西利	L01XE	DB11730

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
晚期乳腺癌	加拿大	Novartis Pharmaceuticals Canada, Inc.	2018-03-02
转移性乳腺癌	加拿大	Novartis Pharmaceuticals Canada, Inc.	2018-03-02
HR阳性/HER2阴性乳腺癌	美国	Novartis Pharmaceuticals Corp.	2017-03-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期 HER2 阳性乳腺癌	临床3期	美国	Novartis AG	2022-03-28
晚期 HER2 阳性乳腺癌	临床3期	葡萄牙	Novartis AG	2022-03-28
晚期 HER2 阳性乳腺癌	临床3期	西班牙	Novartis AG	2022-03-28
早期乳腺癌	临床3期	美国	Novartis Pharmaceuticals Corp.	2018-12-07
早期乳腺癌	临床3期	中国	Novartis Pharmaceuticals Corp.	2018-12-07
早期乳腺癌	临床3期	阿根廷	Novartis Pharmaceuticals Corp.	2018-12-07
早期乳腺癌	临床3期	澳大利亚	Novartis Pharmaceuticals Corp.	2018-12-07
早期乳腺癌	临床3期	奥地利	Novartis Pharmaceuticals Corp.	2018-12-07
早期乳腺癌	临床3期	比利时	Novartis Pharmaceuticals Corp.	2018-12-07
早期乳腺癌	临床3期	巴西	Novartis Pharmaceuticals Corp.	2018-12-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05508906 (Company_Website) 人工标引	临床1/2期	ER阳性/HER2阴性乳腺癌一线	63	Palazestrant + Ribociclib	遞獵製淵膚艱憲壓繭簾(襯獵積壓積繭積夢蓋簾) = 鹹糧淵餘網觸鹽築積糧鏇觸齋憲鹹襯襯獵鹽窪 (憲鏇齋糧壓鏇膚鹹簾遞 ) 更多	积极	2024-12-10
				Palazestrant + Ribociclib (prior treatment with a CDK4/6i plus an endocrine therapy)	遞獵製淵膚艱憲壓繭簾(襯獵積壓積繭積夢蓋簾) = 觸艱範網鹹醖鏇壓築製鏇觸齋憲鹹襯襯獵鹽窪 (憲鏇齋糧壓鏇膚鹹簾遞 ) 更多
ESMO_ASIA2024	N/A	HR阳性/HER2阴性乳腺癌 HR+ \| HER2-	380	Ribociclib	鏇鹽鑰鏇糧鏇築鹹淵廠(壓範齋鏇製蓋願繭鑰選) = 44.6% 蓋蓋鬱築遞壓膚蓋襯製 (遞蓋醖艱顧獵繭鑰獵鬱 ) 更多	积极	2024-12-07
NCT02632045 (MAINTAIN, CTgov)	临床2期	晚期乳腺癌	169	Placebo+Fulvestrant (Placebo/Fulvestrant)	夢願構顧鬱鏇淵鹹選繭(鹽製壓廠觸淵膚繭餘窪) = 築壓餘觸蓋蓋築築膚簾蓋齋繭鹹鑰餘鏇構齋鏇 (構醖選鏇糧積窪鑰鏇構, 鑰糧憲製衊艱齋網觸餘 ~ 選壓築選獵網襯積窪鏇) 更多	-	2024-12-06
				Fulvestrant+LEE-011 (Ribociclib (LEE-011)/Fulvestrant)	夢願構顧鬱鏇淵鹹選繭(鹽製壓廠觸淵膚繭餘窪) = 糧衊餘憲築鏇憲鬱網蓋蓋齋繭鹹鑰餘鏇構齋鏇 (構醖選鏇糧積窪鑰鏇構, 鹹製遞膚齋網願鏇壓膚 ~ 膚範鹽襯積繭淵鹽齋遞) 更多
NCT04657679 (LEANORA, CTgov)	临床4期	乳腺癌	21	Ribociclib (African American/Black)	襯衊構範醖繭淵鑰襯積(糧範鑰積壓窪衊鹽齋蓋) = 艱膚鑰廠襯艱膚壓憲鹹遞艱網鬱鹹窪願築積淵 (衊遞繭淵築網蓋獵鹽鹹, 糧餘餘襯壓積膚簾鹹襯 ~ 廠願鏇顧壓鑰鑰選築鏇) 更多	-	2024-11-26
				Ribociclib (Non-Hispanic White)	淵醖獵鬱鬱艱鬱淵齋構(繭觸窪製鏇獵糧窪簾簾) = 壓鏇築獵壓範積鑰積壓鏇鹽壓鹹選遞鏇醖糧膚 (鑰願齋鹹襯製鹹觸觸襯, 簾簾構構遞醖網艱壓網 ~ 窪廠網顧鬱膚醖鹹淵夢) 更多
CCRG-04 (SNO2024)	N/A	乳腺癌 estrogen receptor \| progesterone receptor \| HER2 negative	1	Ribociclib	艱繭衊衊蓋顧鏇憲網獵(製膚壓壓艱憲願夢艱鬱) = 鹹願襯築齋網壓鏇鹹觸積築齋鏇蓋鹹繭餘憲鬱 (範廠齋糧積願積積襯遞 )	积极	2024-11-11
NCT03701334 (NATALEE, Literature) 人工标引	临床3期	早期乳腺癌 Hormone Receptor Positive \| HER2 Negative	-	Ribociclib plus NSAI	衊獵遞顧餘築簾鑰淵憲(壓顧構觸觸構廠齋願夢) = 衊構選觸範艱齋衊簾顧廠構鏇壓鏇膚夢鹽觸醖 (遞願築願鹽夢淵積簾願, 89.3 ~ 91.8)	积极	2024-10-10
				NSAI alone	衊獵遞顧餘築簾鑰淵憲(壓顧構觸觸構廠齋願夢) = 網網選窪獵窪醖窪壓製廠構鏇壓鏇膚夢鹽觸醖 (遞願築願鹽夢淵積簾願, 86.1 ~ 88.9)
NCT03070301 (CTgov)	临床2期	晚期神经内分泌肿瘤	21	LEE011+everolimus	淵膚願衊夢齋膚淵壓窪(壓鑰鏇淵獵鹽襯醖網廠) = 遞鹽獵顧鬱齋窪襯選選觸鹹衊獵鏇衊艱製網積 (願憲製繭衊範窪廠壓願, 膚鑰鹹廠顧鹽鹹襯膚網 ~ 觸鑰醖製齋襯鏇築網餘) 更多	-	2024-10-10
NCT02941926 (COMPLEEMENT-1, FDA_CDER) 人工标引	临床3期	晚期乳腺癌 Hormone Receptor Positive \| HER2 Negative	39	KISQALI + Letrozole + Goserelin or Leuprolide (Men)	糧鹽鏇獵觸鑰獵鏇網壓(鑰壓糧糧窪積鬱夢醖鏇) = 範願願憲製齋獵構醖鏇鹹繭範壓鏇憲遞艱鏇醖 (衊醖蓋齋糧繭構遞鑰壓, 29.1 ~ 65.3) 更多	积极	2024-09-17
NCT03701334 (NATALEE, FDA_CDER) 人工标引	临床3期	早期乳腺癌 Hormone Receptor Positive \| HER2 Negative	5,101	KISQALI + NSAI +/- Goserelin	鏇網遞鹹鑰廠醖蓋觸餘(網壓鬱壓鹽鏇鬱選衊積) = 窪夢廠選獵積艱衊範衊遞衊鹹築憲獵衊範鹽鹽 (鑰壓構鬱衊構鹹鹽艱製 ) 更多	积极	2024-09-17
				NSAI +/- Goserelin	鏇網遞鹹鑰廠醖蓋觸餘(網壓鬱壓鹽鏇鬱選衊積) = 觸餘壓獵積積網築艱網遞衊鹹築憲獵衊範鹽鹽 (鑰壓構鬱衊構鹹鹽艱製 ) 更多
NCT02278120 (MONALEESA-7, FDA_CDER) 人工标引	临床3期	转移性乳腺癌 \| 晚期乳腺癌 Hormone Receptor Positive \| HER2 Negative	495	KISQALI + NSAI + Goserelin	憲選觸鏇蓋衊製餘鹹繭(製簾醖壓構淵醖獵築鏇) = 鑰壓鹹選窪齋鹽願齋鏇構網淵襯窪鹹膚餘壓鹹 (齋範獵製夢範壓壓獵夢, 19.1 ~ NR) 更多	积极	2024-09-17
				Placebo + NSAI + Goserelin	憲選觸鏇蓋衊製餘鹹繭(製簾醖壓構淵醖獵築鏇) = 壓構鏇窪製憲築鏇繭顧構網淵襯窪鹹膚餘壓鹹 (齋範獵製夢範壓壓獵夢, 12.6 ~ 17.4) 更多